PI3K/mTOR dual inhibitor GSK458 and arsenic trioxide exert synergistic anti-tumor effects against ovarian clear cell carcinoma

Ovarian carcinoma is a significant cause of death among all gynecologic malignancies. OCCC originates from endometriosis with recurrent somatic mutations, especially in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA). To testify the key enrichment pathway of combination of GSK458 with As2O3 in OCCC therapy, we use RNA sequence of four therapy groups (Control group, As2O3 (1uM) monotherapy, GSK458 (0.1uM) monotherapy, As2O3 combined with GSK458 group for 48h) in TOV21G cell line. Overall design: The groups were divided into four groups-Control group, As2O3 (1uM) monotherapy, GSK458 (0.1uM) monotherapy, As2O3 combined with GSK458 group for 48h. Total RNA was extracted using the Qiagen RNeasy Mini Kit (Qiagen, Venlo, Netherlands). RNA integrity was evaluated using the Agilent 2100 Bioanalyzer RNA Nano Chip (Agilent Technologies, Santa Clara, CA, USA). There is one sample for each group. Totally there are four samples from four therapy groups.